Intraoperative Radiotherapy in Gastric and Pancreatic Carcinoma: A European Experience

2015 ◽  
pp. 270-283 ◽  
Author(s):  
Felipe A. Calvo ◽  
Manuel Santos ◽  
Oscar Abuchaibe ◽  
Ignacio Azinovic ◽  
David Ortiz de Urbina ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Intraoperative Radiotherapy ◽  
European Experience

Intraoperative radiotherapy for resectable and unresectable pancreatic carcinoma

1994 ◽  
Vol 1 (3) ◽  
pp. 252-256 ◽  
Author(s):  
Akimasa Nakao ◽  
Akio Harada ◽  
Toshiaki Nonami ◽  
Tetsuya Kaneko ◽  
Soichiro Inoue ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Intraoperative Radiotherapy

Intraoperative radiotherapy for pancreatic carcinoma

1995 ◽  
Vol 82 (9) ◽  
pp. 1259-1261 ◽  
Author(s):  
R. Kasperk ◽  
P. Klever ◽  
D. Andreopoulos ◽  
V. Schumpelick
Keyword(s):  
Pancreatic Carcinoma ◽  
Intraoperative Radiotherapy

Combined modality therapy for stage II and stage III pancreatic carcinoma.

1997 ◽  
Vol 15 (8) ◽  
pp. 2920-2927 ◽  
Author(s):  
A G Kamthan ◽  
J C Morris ◽  
J Dalton ◽  
J P Mandeli ◽  
M R Chesser ◽  
...  
Keyword(s):  
Survival Time ◽  
Pancreatic Carcinoma ◽  
Median Survival ◽  
Median Survival Time ◽  
Residual Disease ◽  
Intraoperative Radiotherapy ◽  
Complete Resection ◽  
Stage Ii ◽  
Primary Tumors ◽  
Gastrointestinal Complications

PURPOSE To study the outcome achieved with three-drug chemotherapy and split-course external-beam radiotherapy as a treatment for unresectable stage II and III pancreatic carcinoma. PATIENTS AND METHODS Radiotherapy was given in three cycles of 2 Gy/d on days 1 to 5 and 8 to 12 (total dose, 54 Gy) concurrently with fluorouracil (FU) 1,000 mg/m2/d by continuous infusion for 4.5 days, streptozocin (STZ) 300 mg/m2 on days 1, 2, and 3 and cisplatin (P) 100 mg/m2 on day 3 of each every-28-day cycle. Subsequent treatment consisted of leucovorin (LV) 200 mg/m2 and FU 600 to 1,000 mg/m2 every 14 days. RESULTS The median survival time for the 35 patients was 15 months and 26% of patients were alive at 24 months. Fifteen patients (42.8%) had objective responses to therapy. Six (17%) had a complete response (CR). Three of nine patients with partial responses (PRs) achieved a radiographic CR within the next 3 months. Nine patients underwent attempts at surgical resection: five were resected (median survival time, 31 months; range, 12.8 to 44.7+), two had no residual disease found at complete resection, and three others also had a complete resection. Of four others who could not be resected, three underwent intraoperative radiotherapy and one had occult metastatic disease. Of primary tumors, 91% did not produce either back pain or local gastrointestinal complications for 2 years. The rates of severe side effects were stomatitis 15%, anemia 14%, granulocytopenia 6%, and thrombocytopenia 6%. CONCLUSION Palliation and survival compare favorably with other series, including many surgical series. The response findings encourage studies of both unresectable and (as neoadjuvant therapy) resectable tumors.

scholarly journals Effect of intraoperative radiotherapy on pancreatic carcinoma: Histopathological findings from autopsy cases.

1988 ◽  
Vol 156 (3) ◽  
pp. 211-219 ◽  
Author(s):  
NARIHIDE GOSEKI ◽  
MORIO KOIKE ◽  
ATSUTAKE OKAMOTO ◽  
TOKIO ONODERA ◽  
TADAYOSHI MATSUDA
Keyword(s):  
Pancreatic Carcinoma ◽  
Intraoperative Radiotherapy ◽  
Histopathological Findings

Immunotherapy of pancreatic carcinoma with siRNA targeting TGF-beta

2009 ◽  
Vol 47 (10) ◽  
Author(s):  
J Ellermeier ◽  
J Wie ◽  
P Düwell ◽  
S Endres ◽  
M Schnurr
Keyword(s):  
Pancreatic Carcinoma ◽  
Tgf Beta
Sign in / Sign up

Export Citation Format

Share Document